Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||905942|
|出版日||ページ情報||英文 147 Pages
|難治性慢性咳嗽（CRC）- 市場洞察、疫学、予測 Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast - 2028|
|出版日: 2019年08月01日||ページ情報: 英文 147 Pages||
DelveInsight's 'Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Refractory Cough (CRC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Chronic Refractory Cough (CRC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Study Period: 2017-2028
Chronic refractory cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialties: Pulmonology, Allergy, and Immunology, Digestive Health and Otorhinolaryngology. Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. It can result in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough, chronic idiopathic cough, unexplained chronic cough, and cough hypersensitivity syndrome. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough which may be localized to the laryngeal region. Chronic cough lasts more than 8 weeks and can be caused by gastroesophageal reflux disease (GERD), postnasal drip from sinus infections or allergies, or chronic lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and interstitial lung diseases.
The DelveInsight Chronic Refractory Cough market report gives the thorough understanding of the Chronic Refractory Cough by including details such as disease introduction, signs and symptoms, causes, risk factors, mechanism of Chronic cough, pathophysiology, the similarity between Chronic Refractory Cough and other neuropathic disorder diagnoses, pathogenesis, clinical features of CRC and diagnosis. It also provides treatment algorithms and treatment guidelines for Chronic Refractory Cough in the US, Europe, and Japan.
In the United States, cough is the most common complaint for which patients seek medical attention and is the second most common reason for a general medical examination, accounting for more than 26 million office visits annually. Cough often results from an acute, self-limited, viral upper respiratory tract infection; however, there are multiple causes of cough beyond this, including both respiratory tract and nonrespiratory tract-related etiologies. Cough that lasts more than 8 weeks is considered to be chronic as per defined by the American College of Chest Physicians (ACCP). The cough becomes chronic if it persists, often due to an underlying etiology that is difficult to diagnose or treat.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Chronic Refractory Cough in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2028 for the following aspects:
According to a study conducted by Jun et al. titled "Effect of pregabalin for the treatment of chronic refractory cough," which stated that nearly 11-16% of patients suffer from chronic refractory cough during their life. Although many patients had received satisfactory treatment, there were still 20-40% of patients who suffered long-term cough symptoms even after standardized treatment. The study was concluded stating that an innovative treatment with fewer adverse effects and long-term relief was necessary for CRC patients.
According to a study conducted by Weinberger et al. titled "Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens" researchers assessed the burden of suffering related to prolonged coughing and tried to identify further causative agents. It was found that incidence of pertussis in adults have shown that it accounted for only approximately 5-15% cases of prolonged coughing in which, symptoms were not indicative of a specific agent and a total of 64% of patients received antibiotics. The study was concluded by stating that prolonged adult coughing required medical attention, which prompted substantial healthcare use.
This segment of the Chronic Refractory Cough report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Chronic Refractory Cough, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Chronic Refractory Cough and awareness of the disease. The overall dynamics of Chronic Refractory Cough market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Merck, Nerre Therapeutics, Bellus Health, Attenua, Respivant Sciences, and Shionogi and Bayer will significantly increase the market during the forecast period (2019-2028).
Chronic refractory cough proves to be a huge burden on the patients who are fighting this debilitating condition. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough, which may be localized to the laryngeal region. It significantly impairs patients' quality of life. Unfortunately, in many situations, patients continue to experience CRC in spite of following published guidelines for diagnosis and treatment.
Currently, the market holds no approved therapy to treat chronic refractory cough. According to the recent guidelines published by the American College of Chest Physicians (ACCP) four categories of treatment can be implemented which include nonpharmacologic therapies, inhaled corticosteroids, neuromodulatory therapies, and other therapies.
The market of CRC is mainly dominated by nonpharmacologic therapies, which include Speech Therapy and Physiotherapy. The market also holds various types of pharmacologic therapies, which include Neuromodulators, Proton pump inhibitors, Inhaled Corticosteroids, and other treatment options. Opiates (morphine, codeine, tramadol, etc.), gabapentin, pregabalin, morphine, amitriptyline, and baclofen, which act on the heightened neural sensitization, and is involved in the pathogenesis of CRC. There are several other treatment options also followed for the CRC patients. Since, CRC is an outcome of several disorders, such as Gastroesophageal reflux disease (GORD), asthma, bronchitis, etc. A drug like esomeprazole, which is a proton pump inhibitor helps in relieving the acid-reflux in cough associated with GOR. Another drug Ipratropium bromide is used as a bronchodilator, which can provide short-term relief from cough.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Chronic Refractory Cough in 7MM is expected to change from 2019 to 2028.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Chronic Refractory Cough (CRC), such as Gefapixant (Merck), RVT-1601 (Respivant Sciences), Orvepitant Maleate (Nerre Therapeutics), BLU-5937 (Bellus Health), Bradanicline (Attenua), S-600918 (Shionogi), BAY1902607 and BAY1817080 (Bayer), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Chronic Refractory Cough (CRC) market.